Mobile

Randomized Phase III, Double-Blind, Placebo-Controlled Multicenter Trial of Everolimus in Combination with Trastuzumab and Paclitaxel, as First Line Therapy in Women with HER2 Positive Locally Advance...

Mise à jour : Il y a 4 ans
Référence : EUCTR2008-006556-21

Randomized Phase III, Double-Blind, Placebo-Controlled Multicenter Trial of Everolimus in Combination with Trastuzumab and Paclitaxel, as First Line Therapy in Women with HER2 Positive Locally Advanced or Metastatic Breast Cancer

Femme Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To compare progression free survival (PFS) between combination treatment of everolimus/ trastuzumab/ paclitaxel and the combination treatment with trastuzumab/paclitaxel.

Critère d'inclusion

  • HER2+ locally advanced or metastatic breast cancer

Liens